Tadalafil Tablet, Film Coated
Product Images NDC 72603-782

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72603-782). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

"image Description" (Tadalafil 10mg 1000s Bottle Label)

Label for Tadalafil Tablets USP 10 mg, film-coated oral tablets, showing package size of 1000 tablets. Manufactured by Umedica Laboratories Pvt. Ltd., India, and labeled for NorthStar Rx LLC. The label includes storage instructions, warnings, and a barcode, with NorthStar branding.*

FDA Label Image

"image Description" (Tadalafil 20mg 1000s Bottle Label)

Label for Tadalafil Tablets, USP 20 mg film-coated tablets by NorthStar Rx, LLC. The label shows 1000 tablets in the package, with storage instructions and manufacturer details: Umedica Laboratories Pvt. Ltd., India. The label includes warnings and dosage instructions referencing accompanying literature.*

FDA Label Image

"image Description" (Tadalafil 2pt5mg 1000s Bottle Label)

Tadalafil Tablets, USP 2.5 mg film-coated tablets label for a prescription product by NorthStar Rx, LLC. The label indicates a quantity of 1000 tablets. It includes storage instructions, warnings, manufacturer details including Umedica Laboratories Pvt. Ltd. in India, and the product is manufactured for NorthStar Rx LLC in Memphis, TN.*

FDA Label Image

"image Description" (Tadalafil 5mg 1000s Bottle Label)

Tadalafil Tablets, USP 5 mg film-coated oral tablets, labeled for prescription use only. The label indicates a package size of 1000 tablets. Manufactured by Umedica Laboratories Pvt. Ltd. in India and distributed by Northstar Rx LLC. Includes storage instructions and barcode on the label.*

FDA Label Image

"image Description" (Tadalafil Figure 1)

Four line graphs displaying blood pressure changes over 96 hours comparing tadalafil versus placebo. The graphs show differences in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure in mmHg, with time on the x-axis and pressure difference on the y-axis. Each graph includes error bars for variability.*

FDA Label Image

"image Description" (Tadalafil Figure 2)

This image contains two line graphs showing standing and supine systolic blood pressure (BP) changes measured in mmHg over 24 hours post-dose. The graphs compare the effects of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg. The x-axis represents time post-dose in hours, and the y-axis shows systolic BP change ranging from -20 to 10 mmHg.*

FDA Label Image

"image Description" (Tadalafil Figure 3)

A line graph depicting systolic blood pressure (mmHg) over time after administration of tadalafil or placebo with doxazosin. It shows four data series comparing 20 mg tadalafil and placebo at different dosing times (08:00 and 20:00), illustrating fluctuations in blood pressure within 12 hours post-administration.*

FDA Label Image

"image Description" (Tadalafil Figure 4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens: single 20 mg dose, single 5 mg dose, and once-daily 5 mg dose following 5 consecutive days of administration. Concentration peaks early and declines over time, with error bars indicating variability at each time point.*

FDA Label Image

"image Description" (Tadalafil Figure 5)

Line graph comparing the effect of Tadalafil 5 mg tablets versus placebo over 12 weeks on change from baseline in IPSS total score. The graph shows a greater decrease in IPSS score with Tadalafil 5 mg than placebo, indicating improved symptoms, with data points at 0, 4, 8, and 12 weeks. Statistical significance is noted with P < 0.01 at 12 weeks.*

FDA Label Image

"image Description" (Tadalafil Figure 6)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment duration comparing Tadalafil 5 mg tablets and placebo. The graph includes data points at 0, 1, 4, 8, and 12 weeks, with Tadalafil showing a greater decrease in IPSS score over time compared to placebo. Statistical significance is indicated for some time points (P < 0.01).*

FDA Label Image

"image Description" (Tadalafil Figure 7)

A line graph showing least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride to Placebo/Finasteride. The graph plots data points at 0, 4, 12, and 26 weeks, with Tadalafil/Finasteride showing a greater decrease from baseline than Placebo/Finasteride. Significant differences at weeks 4, 12, and 26 are indicated with statistical annotations (p<0.001 and p<0.05).*

FDA Label Image

"image Description" (Tadalafil Figure 8)

A line graph illustrating the change from baseline in IPSS total score over 12 weeks of treatment with Tadalafil 5 mg tablets versus placebo. The x-axis represents duration of treatment in weeks, and the y-axis indicates change from baseline in IPSS total score. The graph shows a greater decrease in score for Tadalafil compared to placebo, with statistical significance noted at 12 weeks (p<0.01).*

FDA Label Image

"image Description" (Tadalafil Structure)

Chemical structure of Tadalafil, depicting its molecular framework with labeled rings and functional groups as shown in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.